Xia Q, Nie H, Chen D, Chen J, Tian Y, Zhang J
Department of General Surgery, Xiehe Hospital, Tongji Medical University, Wuhan 430022.
J Tongji Med Univ. 1999;19(3):219-22. doi: 10.1007/BF02887739.
A new targeting anticancer system was prepared by using hydroxyapatite particles (2 mm in diameter) as carrier material and adriamycin as anticancer agent. The adsorption and release properties of the complexes were assayed by fluorometry in vivo and in vitro and the curative effect on W-256 sarcoma of rat was observed. The results showed that one particle of hydroxyapatite could adsorb approximately 0.08 mg adriamycin and they can maintain a steady and slow release of adriamycin from hydroxyapatite for one month. When hydroxyapatite-adriamycin complexes were implanted into the liver of rat, liver adriamycin concentration at the implanted region was obviously higher than that achieved by injection of adriamycin solution. The locally implanted complexes obviously inhibited the growth of subcutaneous implanted tumor of rat, and increased the survival rate of rat with implanted liver tumor.
以直径为2毫米的羟基磷灰石颗粒为载体材料、阿霉素为抗癌剂，制备了一种新型靶向抗癌系统。通过荧光分析法在体内和体外测定了复合物的吸附和释放特性，并观察了其对大鼠W-256肉瘤的治疗效果。结果表明，一粒羟基磷灰石可吸附约0.08毫克阿霉素，且能使阿霉素从羟基磷灰石中持续稳定缓慢释放一个月。将羟基磷灰石-阿霉素复合物植入大鼠肝脏后，植入部位的肝脏阿霉素浓度明显高于注射阿霉素溶液所达到的浓度。局部植入的复合物明显抑制了大鼠皮下植入肿瘤的生长，并提高了植入肝脏肿瘤大鼠的存活率。
